Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $1.93 Average Target Price from Brokerages

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $1.93.

Separately, D. Boral Capital dropped their price target on Carisma Therapeutics from $12.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st.

Institutional Investors Weigh In On Carisma Therapeutics

A hedge fund recently raised its stake in Carisma Therapeutics stock. Barclays PLC raised its position in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) by 3,661,933.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 549,305 shares of the company’s stock after purchasing an additional 549,290 shares during the period. Barclays PLC owned 1.32% of Carisma Therapeutics worth $539,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Trading Down 4.4 %

Shares of CARM stock opened at $0.19 on Wednesday. Carisma Therapeutics has a 52-week low of $0.16 and a 52-week high of $1.91. The company has a 50-day simple moving average of $0.35 and a two-hundred day simple moving average of $0.58. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market capitalization of $8.02 million, a price-to-earnings ratio of -0.12 and a beta of 1.56.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.